Remdesivir: The race against COVID-19

The world came to a standstill as a result of the COVID pandemic announced in March 2020. Currently, there are about 100 companies looking for the solution to the Coronavirus infection through vaccine and or medicine.

The situation is fluid and challenging to follow. Information is constantly changing as we learn more about this virus.

The latest in the fight against the coronavirus was the announcement by America’s FDA of the emergency use authorization of a drug called Remdesivir in severe COVID-19 disease. In a clinical trial of the use of Remdesivir, there was a reduction in mortality from 11.6% to 8% in severe COVID-19 disease.

Remdesivir is given intravenously in people with severe disease as shown by oxygen saturation of less than or equal to 94%, on mechanical ventilation or on ECMO (extracorporeal membrane oxygenation).

Side effects of Remdesivir include liver and kidney dysfunction.

For additional information refer to the source article.

Additional reading on COVID-19

Image: Random picture from GoDaddy stock photos

To share this post

Leave a Reply

Your email address will not be published. Required fields are marked *